Latest news

  • 23 April 2018

    Sensorion and Uconn Health Announce Identification of First Potential Biomarker for Noise-Induced Hearing Loss. Read

  • 23 April 2018

    Sensorion’s SENS-401 Reduces Hearing Loss in Preclinical Study When Oral Administration Initiated Up to Four Days after Acoustic Trauma. Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more